So, Rezvani and her MD Anderson colleagues started with NK cells from cord blood and engineered them to include genes for a CAR that targets CD19 — a protein on the surface of all B cells ...

However, the conventional process of human NK cell expansion faces unique cell culture challenges for clinically relevant applications, including a particular need for modularity, standardization, and ...

told the conference that her lab has been able to make natural killer cells targeting CD19, a biomarker found on the surface of certain blood cancer cells. Unmodified natural killer (NK ...

The Engager platform is a differentiated technology that coats the surface of NK cells with biomaterial composite materials to maximize the precise targeting of cancer cells and the anticancer ...